leading the future of early Screening
Our advanced nanoscale technology and AI analyze mRNA from a simple cheek swab, offering insights into a broad range of potential health risks, including various cancers and inflammatory conditions.
These samples were collected in 40 clinics in the United States according to an IRB approved clinical protocol.
Hundreds of peer-reviewed articles in renowned publications support our scientific breakthrough.
Our team is made up of leading experts in health, experienced AI technologists, and skilled operators. A CAP CLIA certified lab collects, validates and analyzes our extensive and growing patient samples.
01
Growing home screening market
02
First-mover advantage with RNA-focused tests
03
Clear path to Scalablity
